Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Optimization of tumor xenograft dissociation for the profiling of cell surface markers and nutrient transporters.
Petit V, Massonnet G, Maciorowski Z, Touhami J, Thuleau A, Némati F, Laval J, Château-Joubert S, Servely JL, Vallerand D, Fontaine JJ, Taylor N, Battini JL, Sitbon M, Decaudin D. Petit V, et al. Among authors: thuleau a. Lab Invest. 2013 May;93(5):611-21. doi: 10.1038/labinvest.2013.44. Epub 2013 Mar 4. Lab Invest. 2013. PMID: 23459372 Free article.
Acquired resistance to endocrine treatments is associated with tumor-specific molecular changes in patient-derived luminal breast cancer xenografts.
Cottu P, Bièche I, Assayag F, El Botty R, Chateau-Joubert S, Thuleau A, Bagarre T, Albaud B, Rapinat A, Gentien D, de la Grange P, Sibut V, Vacher S, Hatem R, Servely JL, Fontaine JJ, Decaudin D, Pierga JY, Roman-Roman S, Marangoni E. Cottu P, et al. Among authors: thuleau a. Clin Cancer Res. 2014 Aug 15;20(16):4314-25. doi: 10.1158/1078-0432.CCR-13-3230. Epub 2014 Jun 19. Clin Cancer Res. 2014. PMID: 24947930
Activation of IFN/STAT1 signalling predicts response to chemotherapy in oestrogen receptor-negative breast cancer.
Legrier ME, Bièche I, Gaston J, Beurdeley A, Yvonnet V, Déas O, Thuleau A, Château-Joubert S, Servely JL, Vacher S, Lassalle M, Depil S, Tucker GC, Fontaine JJ, Poupon MF, Roman-Roman S, Judde JG, Decaudin D, Cairo S, Marangoni E. Legrier ME, et al. Among authors: thuleau a. Br J Cancer. 2016 Jan 19;114(2):177-87. doi: 10.1038/bjc.2015.398. Epub 2015 Dec 22. Br J Cancer. 2016. PMID: 26695443 Free PMC article.
Characterization of Breast Cancer Preclinical Models Reveals a Specific Pattern of Macrophage Polarization.
Vallerand D, Massonnet G, Kébir F, Gentien D, Maciorowski Z, De la Grange P, Sigal-Zafrani B, Richardson M, Humbert S, Thuleau A, Assayag F, de Plater L, Nicolas A, Scholl S, Marangoni E, Weigand S, Roman-Roman S, Savina A, Decaudin D. Vallerand D, et al. Among authors: thuleau a. PLoS One. 2016 Jul 7;11(7):e0157670. doi: 10.1371/journal.pone.0157670. eCollection 2016. PLoS One. 2016. PMID: 27388901 Free PMC article.
Pyrophosphorolysis-activated polymerization detects circulating tumor DNA in metastatic uveal melanoma.
Madic J, Piperno-Neumann S, Servois V, Rampanou A, Milder M, Trouiller B, Gentien D, Saada S, Assayag F, Thuleau A, Nemati F, Decaudin D, Bidard FC, Desjardins L, Mariani P, Lantz O, Stern MH. Madic J, et al. Among authors: thuleau a. Clin Cancer Res. 2012 Jul 15;18(14):3934-41. doi: 10.1158/1078-0432.CCR-12-0309. Epub 2012 May 29. Clin Cancer Res. 2012. PMID: 22645051
Predictive gene signature of response to the anti-TweakR mAb PDL192 in patient-derived breast cancer xenografts.
de Plater L, Vincent-Salomon A, Berger F, Nicolas A, Vacher S, Gravier E, Thuleau A, Karboul N, Richardson M, Elbaz C, Marangoni E, Bièche I, Paoletti X, Roman-Roman S, Culp PA, Asselain B, Diéras V, Decaudin D. de Plater L, et al. Among authors: thuleau a. PLoS One. 2014 Nov 6;9(11):e104227. doi: 10.1371/journal.pone.0104227. eCollection 2014. PLoS One. 2014. PMID: 25375638 Free PMC article.
A New Transcutaneous Method for Breast Cancer Detection with Dogs.
Thuleau A, Gilbert C, Bauër P, Alran S, Fourchotte V, Guillot E, Vincent-Salomon A, Kerihuel JC, Dugay J, Semetey V, Kriegel I, Fromantin I. Thuleau A, et al. Oncology. 2019;96(2):110-113. doi: 10.1159/000492895. Epub 2018 Oct 2. Oncology. 2019. PMID: 30278460
AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) In Vivo.
Ribas R, Pancholi S, Guest SK, Marangoni E, Gao Q, Thuleau A, Simigdala N, Polanska UM, Campbell H, Rani A, Liccardi G, Johnston S, Davies BR, Dowsett M, Martin LA. Ribas R, et al. Among authors: thuleau a. Mol Cancer Ther. 2015 Sep;14(9):2035-48. doi: 10.1158/1535-7163.MCT-15-0143. Epub 2015 Jun 26. Mol Cancer Ther. 2015. PMID: 26116361
17 results